ChemoCentryx’s Oral PD-L1 inhibitor, CCX559, Featured in Poster Presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting

-- CCX559 enhanced primary human T cell activity in vitro and demonstrated anti-tumor efficacy in two murine tumor models --

-- Company plans to advance CCX559 into clinical development in the first half of 2021 --

MOUNTAIN VIEW, CA, USA I April 09, 2021 I ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company’s orally-administered small molecule PD-L1 inhibitor, CCX559, will be featured in a poster presentation at the virtual 2021 Annual Meeting of the American Association for Cancer Research (AACR). The poster presentation, which showcases CCX559’s ability to induce anti-tumor immunity, will go live on Saturday, April 10 at 8:30 a.m. ET as part of the Novel Antitumor Agents Session (PO.ET06.03).

PD-L1/PD-1 interaction is one of the major checkpoints that limit effector T cell function against cancer cells. As a next generation therapy, small molecule inhibitors of PD-L1 may have advantageous properties compared to approved monoclonal antibodies, such as better penetration into solid tumors, reduced immunogenicity, lack of Fc-mediated side effects, convenience of oral administration, and lower cost of goods.

The study featured in the AACR poster presentation demonstrated that CCX559 potentially employs distinct mechanisms to inhibit PD-L1 compared to the anti-human PD-L1 antibodies. In murine tumor models, orally administered CCX559 reduced tumor growth similarly to a clinically-approved anti-human PD-L1 antibody.

Based on CCX559’s unique mechanism of PD-L1 inhibition, strong anti-tumor activity, desirable drug properties, and good safety profile, the Company plans to advance CCX559 into clinical development in the first half of 2021.

About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 Glomerulopathy (C3G).

ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

SOURCE: ChemoCentryx

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up